非小細胞肺癌患者第一線藥物之多目標分析- 醫療成效與成本

以作者查詢圖書館館藏

、以作者查詢臺灣博碩士

、以作者查詢全國書目

、勘誤回報

、線上人數：14

、訪客IP：18.225.56.194

姓名

李旻嘉(Min-Chia Lee) 查詢紙本館藏

畢業系所

工業管理研究所

論文名稱

非小細胞肺癌患者第一線藥物之多目標分析- 醫療成效與成本
(Multiple objective analysis of first line medicine with non-small cell lung cancer – medical effect and medical cost)

相關論文

★ 利用貝氏網路分析肺癌患者使用標靶藥物與其他藥物之交互作用

檔案

[Endnote RIS 格式]

[Bibtex 格式]

[相關文章]

[文章引用]

[完整記錄]

[館藏目錄]

[檢視]

[下載]

本電子論文使用權限為同意立即開放。
已達開放權限電子全文僅授權使用者為學術研究之目的，進行個人非營利性質之檢索、閱讀、列印。
請遵守中華民國著作權法之相關規定，切勿任意重製、散佈、改作、轉貼、播送，以免觸法。

摘要(中)

肺癌的標準治療為化療以及標靶藥物，然而根據病人的身體狀況，可以在使用化療藥物時同時也使用鉑化物。醫生在選擇治療方式時，一定會為病患選擇最適合的治療方式。從西元1995年開始，台灣就有全民健康保險。因為有全民健保的關係，台灣的病患可以用低廉的價格享受良好的醫療資源，因此在得到癌症後，大家都可獲得良好的治療。但因現今健保即將面臨破產的危機，在有限的資源中，我們必須有所取捨。在得到癌症時，醫生會盡可能地幫病患延長生命，然而每一種藥藥效不同，價格也不同。在這個情況下，根據不同病患的狀況，找出哪種藥物的藥效最好，且醫療花費沒那麼高的治療方式就相當的重要。而且在單一醫療項目支出過多也會排擠到其他疾病的健保補助。在過去的研究中，都是在探討哪一種藥物、哪一種治療方式對於病患的存活是最好的，因為人的生命都是無價的，忽略了醫療成本的部分，因此在本篇論文中，會使用層級分析法(AHP)結合醫療效果以及醫療成本做出一個指標去衡量不同的治療方式。

摘要(英)

The standard treatments of lung cancer are chemotherapy and targeted drug. Depending on patients’ physical condition, doctors decide if they need to compound with Cisplatin or Carboplatin, when patients receive chemotherapy. When doctors make decision, they consider about which treatment can provide patients better surviving. Since 1995, Taiwan launch National Health Insurance. Because of it, Taiwanese can receive medical treatment in a low price. However, National Health Insurance is facing bankruptcy. Therefore, it is important to find which treatment provide good medical effect and low medical cost. Moreover, when it is subsided a lot in one disease, it edges out the others subsidies. In previous research, they focus on which treatment can provide high survival rate. They ignore the medical cost. In this thesis, we will use analytic hierarchy process (AHP) to combine medical effect and medical cost. In addition, we will form a score to evaluate each treatment under different situation.

關鍵字(中)

★ 存活分析
★ 層級分析法
★ 非小細胞肺癌

關鍵字(英)

★ survival analysis
★ AHP
★ non-small cell lung cancer

論文目次

摘要 i
Abstract ii
Contents iii
List of Table iv
Chapter 1 Introduction 1
1-1 Research Background 1
1-2 Research Motivation and Objectives 2
1-3 Research Environment 3
Chapter 2 Literature Review 6
2-1 Decision Making 6
2-2 Analytic Hierarchy Process 6
2-3 Non-Small-Cell lung cancer 7
Chapter 3 Methodology 9
3-1 Survival Analysis 9
3-2 Analytic Hierarchy Process 11
Chapter 4 Result 15
4-1 Survival Analysis 15
4-1-1 Survival Analysis of Treatment 15
4-1-2 Survival Analysis of Medicine 21
4-2 Evaluation Treatment Alternatives based on AHP 25
4-3 Analysis with the AHP and Database 27
4-3-1 Score of each Treatment 28
4-3-2 Score under Different Medicine of Chemotherapy 29
Chapter 5 Conclusion and Future Work 34
Reference 37

參考文獻

[1] Bellman, R. E., and Zardeh, L. A., “Decision-Making in a Fuzzy Environment”, Management Science, Vol. 17, No. 4, pp. B141-B164, 1970.
[2] Brunelli, Matteo, “Introduction to the Analytic Hierarchy Process”, Springer Briefs In Operation Research, 2015.
[3] Cao, Jun, Yang, He, Liu, Hong-Qiang, Wang, Sai-Bo, Zhao, Bao-Cheng, and Cheng, Ying-Sheng, “MicroRNA 192 regulates chemo-resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl-2”, International Journal of Clinical and Experimental Medicine, 8(8), pp.12397–12403, 2015.
[4] Larsen, Jill E., Cascone, Tina, Gerber, David E., Heymach, John V., and Minna, John D., “Targeted Therapies for Lung Cancer”, The Cancer Journal, 17(6), pp. 512–527,2011.
[5] Lin, C. S. and Harris, S. L., “A unified framework for the prioritization of organ transplant patients: Analytic hierarchy process, sensitivity and multifactor robustness study” Journal of Multi-Criteria Decision Analysis, 20(3-4), pp.157–172, 2013.
[6] Lindeman, Neal I., Cagle, Philip T., Beasley, Mary Beth, Chitale, Dhananjay Arun, Dacic, Sanja, Giaccone, Giuseppe, Jenkins, Robert Brian, Kwiatkowski, David J., Saldivar, Juan-Sebastian, Squire, Jeremy, Thunnissen, Erik, and Ladanyi, Marc, “Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors” Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. 2013.
[7] Merton, Robert C, “Aa analytic derivation of the efficient portfolio frontier”, Journal of Financial & Quantitative Analysis. Vol. 7 Issue 4, p1851-1872, 1972.
[8] Mok, Tony S., Wu, Yi-Long, Thongprasert, Sumitra, Yang, Chih-Hsin, Chu, Da-Tong, Saijo, Nagahiro, Sunpaweravong, Patrapim, Han, Baohui, Margono, Benjamin, Ichinose, Yukito, Nishiwaki, Yutaka and Ohe, Yuichiro “Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma”, New England Journal of Med, 361(10), pp.947-57, 2009.
[9] Savic, Milan, Kontic, Milica, Ercegovac, Maja, Stojsic, Jelena, Bascarevic, Slavisa, Moskovljevic, Dejan, Kostic, Marko, Vesovic, Radomir, Popevic, Spasoje, Laban, Marija, Markovic, Jelena, and Jovanovic, Dragana “Comparison of mediastinal lymph node status and relapse pattern in clinical stage IIIA non‐small cell lung cancer patients treated with neoadjuvant chemotherapy versus upfront surgery: A single center experience”, Thorac Cancer, 8(5), pp. 393–401, 2017.
[10] Saaty, T.L., “Decision making with the analytic hierarchy process”, Int. J. Services Sciences, Vol. 1, No. 1, pp.83–98., 2008.
[11] Saaty, T. L., “Absolute and relative measurement with the AHP. The most livable cities in the United States” Socio-Economic Planning Sciences, 20(6):327–331, 1986.
[12] Wind, Yoram and, Saaty, Thomas L., “Marketing Applications of the Analytic Hierarchy Process”, Management Science, Vol. 26, No. 7, pp. 641-658, 1980.

指導教授

曾富祥枋岳甫(Fu-Shiang Tseng Yueh-Fu Fang)

審核日期

2018-7-10

推文